Alternative dosing schedules for cetuximab: A role for biweekly administration?

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

The anti-epidermal growth factor receptor targeted monoclonal antibody (MoAb) cetuximab has established efficacy as a single agent and in combination with other modalities (chemotherapy, radiation therapy) in head and neck cancer and metastatic colorectal cancer. The agent is typically administered weekly; however, the development of a biweekly dosing regimen for cetuximab would provide treatment flexibility when combined with biweekly or longer chemotherapy regimens. The feasibility for biweekly dosing with cetuximab is supported by several factors. Biweekly dosing with MoAbs has been effective in multiple tumor types. Although cetuximab is currently administered on a weekly schedule, pharmacokinetic data demonstrate that cetuximab has a long terminal half-life, allowing administration of a biweekly schedule. Results from phase I studies show that a biweekly schedule of cetuximab is well tolerated, exhibits similar pharmacokinetics and pharmacodynamics to conventional weekly dosing, and does not seem to compromise efficacy. Additional studies are therefore warranted to further evaluate biweekly dosing for cetuximab in order to optimize treatment outcomes and convenience for patients.

Original languageEnglish (US)
Pages (from-to)364-368
Number of pages5
JournalClinical Colorectal Cancer
Volume7
Issue number6
DOIs
StatePublished - 2008
Externally publishedYes

Fingerprint

Appointments and Schedules
Pharmacokinetics
Drug Therapy
Head and Neck Neoplasms
Cetuximab
Epidermal Growth Factor Receptor
Half-Life
Colorectal Neoplasms
Radiotherapy
Monoclonal Antibodies
Neoplasms

Keywords

  • EGFR
  • FOLFIRI
  • Monoclonal antibody
  • Squamous cell carcinoma of the head and neck

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

Alternative dosing schedules for cetuximab : A role for biweekly administration? / Ramanathan, Ramesk K.

In: Clinical Colorectal Cancer, Vol. 7, No. 6, 2008, p. 364-368.

Research output: Contribution to journalReview article

@article{8fcf3be8f753459f88fa424abfb1a44c,
title = "Alternative dosing schedules for cetuximab: A role for biweekly administration?",
abstract = "The anti-epidermal growth factor receptor targeted monoclonal antibody (MoAb) cetuximab has established efficacy as a single agent and in combination with other modalities (chemotherapy, radiation therapy) in head and neck cancer and metastatic colorectal cancer. The agent is typically administered weekly; however, the development of a biweekly dosing regimen for cetuximab would provide treatment flexibility when combined with biweekly or longer chemotherapy regimens. The feasibility for biweekly dosing with cetuximab is supported by several factors. Biweekly dosing with MoAbs has been effective in multiple tumor types. Although cetuximab is currently administered on a weekly schedule, pharmacokinetic data demonstrate that cetuximab has a long terminal half-life, allowing administration of a biweekly schedule. Results from phase I studies show that a biweekly schedule of cetuximab is well tolerated, exhibits similar pharmacokinetics and pharmacodynamics to conventional weekly dosing, and does not seem to compromise efficacy. Additional studies are therefore warranted to further evaluate biweekly dosing for cetuximab in order to optimize treatment outcomes and convenience for patients.",
keywords = "EGFR, FOLFIRI, Monoclonal antibody, Squamous cell carcinoma of the head and neck",
author = "Ramanathan, {Ramesk K}",
year = "2008",
doi = "10.3816/CCC.2008.n.048",
language = "English (US)",
volume = "7",
pages = "364--368",
journal = "Clinical Colorectal Cancer",
issn = "1533-0028",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Alternative dosing schedules for cetuximab

T2 - A role for biweekly administration?

AU - Ramanathan, Ramesk K

PY - 2008

Y1 - 2008

N2 - The anti-epidermal growth factor receptor targeted monoclonal antibody (MoAb) cetuximab has established efficacy as a single agent and in combination with other modalities (chemotherapy, radiation therapy) in head and neck cancer and metastatic colorectal cancer. The agent is typically administered weekly; however, the development of a biweekly dosing regimen for cetuximab would provide treatment flexibility when combined with biweekly or longer chemotherapy regimens. The feasibility for biweekly dosing with cetuximab is supported by several factors. Biweekly dosing with MoAbs has been effective in multiple tumor types. Although cetuximab is currently administered on a weekly schedule, pharmacokinetic data demonstrate that cetuximab has a long terminal half-life, allowing administration of a biweekly schedule. Results from phase I studies show that a biweekly schedule of cetuximab is well tolerated, exhibits similar pharmacokinetics and pharmacodynamics to conventional weekly dosing, and does not seem to compromise efficacy. Additional studies are therefore warranted to further evaluate biweekly dosing for cetuximab in order to optimize treatment outcomes and convenience for patients.

AB - The anti-epidermal growth factor receptor targeted monoclonal antibody (MoAb) cetuximab has established efficacy as a single agent and in combination with other modalities (chemotherapy, radiation therapy) in head and neck cancer and metastatic colorectal cancer. The agent is typically administered weekly; however, the development of a biweekly dosing regimen for cetuximab would provide treatment flexibility when combined with biweekly or longer chemotherapy regimens. The feasibility for biweekly dosing with cetuximab is supported by several factors. Biweekly dosing with MoAbs has been effective in multiple tumor types. Although cetuximab is currently administered on a weekly schedule, pharmacokinetic data demonstrate that cetuximab has a long terminal half-life, allowing administration of a biweekly schedule. Results from phase I studies show that a biweekly schedule of cetuximab is well tolerated, exhibits similar pharmacokinetics and pharmacodynamics to conventional weekly dosing, and does not seem to compromise efficacy. Additional studies are therefore warranted to further evaluate biweekly dosing for cetuximab in order to optimize treatment outcomes and convenience for patients.

KW - EGFR

KW - FOLFIRI

KW - Monoclonal antibody

KW - Squamous cell carcinoma of the head and neck

UR - http://www.scopus.com/inward/record.url?scp=58849115141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58849115141&partnerID=8YFLogxK

U2 - 10.3816/CCC.2008.n.048

DO - 10.3816/CCC.2008.n.048

M3 - Review article

C2 - 19036688

AN - SCOPUS:58849115141

VL - 7

SP - 364

EP - 368

JO - Clinical Colorectal Cancer

JF - Clinical Colorectal Cancer

SN - 1533-0028

IS - 6

ER -